Afatinib/erlotinib/osimertinib.
In: Reactions Weekly, Jg. 1697 (2018-04-10), Heft 1, S. 22-22
serialPeriodical
Zugriff:
The article presents a case study of a 24-year-old woman with stage IV lung adenocarcinoma and developed various toxicities and developement of drug resistance to afatinib, osimertinib, and erlotinib. The patient with psoriasis and was diagnosed with lung adenocarcinoma was started with treatment with afatinib, tyrosine kinase inhibitor (TKI). The patient developed paronychia, rash and drug resistance following treatment with osimertinib and diarrhoea during treatment with erlotinib.
Titel: |
Afatinib/erlotinib/osimertinib.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 1697 (2018-04-10), Heft 1, S. 22-22 |
Veröffentlichung: | 2018 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-018-44578-0 |
Schlagwort: |
|
Sonstiges: |
|